(Q39493031)

12 September 2017

Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications (English)

1 reference

protein heterodimerization activity

12 September 2017

1 reference

M Sánchez-Martín

1

1 reference

PubMed ID

21826647

12 September 2017

A Pandiella

series ordinal

2

1 reference

PubMed ID

21826647

12 September 2017

language of work or name

English

0 references

publication date

22 September 2011

1 reference

International Journal of Cancer

12 September 2017

1 reference

12 September 2017

131

1 reference

12 September 2017

1

1 reference

12 September 2017

244-252

1 reference

ERBB receptors and cancer: the complexity of targeted inhibitors

12 September 2017

1 reference

The ErbB receptors and their role in cancer progression.

21 January 2018

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

Epidermal growth factor receptor inhibitors in oncology

21 January 2018

1 reference

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

21 January 2018

1 reference

Ligand-induced ErbB receptor dimerization

21 January 2018

1 reference

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment

21 January 2018

1 reference

The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain

21 January 2018

1 reference

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

21 January 2018

1 reference

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

Monoclonal antibody-based targeted therapy in breast cancer.

21 January 2018

1 reference

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy

21 January 2018

1 reference

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

21 January 2018

1 reference

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

21 January 2018

1 reference

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

Epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment

21 January 2018

1 reference

Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells

21 January 2018

1 reference

Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy

21 January 2018

1 reference

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

21 January 2018

1 reference

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

21 January 2018

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

21 January 2018

1 reference

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26358

1 reference

12 September 2017

1 reference

PubMed ID

21826647